The decision regarding discontinuation or maintenance of pharmacologic molecules acting on the coagulation pathway, in preparation of radical prostatectomy (RP), involves a trade-off between the risks of venous thromboembolism and major bleeding. This topic, although investigated in open RP series, has been poorly addressed in contemporary robot-assisted RP (RARP) cases.